Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. 1987

S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag

The influence of multiple doses of ofloxacin (ORF 18489) on the disposition of theophylline was studied in 15 male volunteers. Subjects were confined in the Clinical Research Unit for 13 days and given a xanthine-free diet. A single dose (3 mg/kg) of theophylline was given orally, and blood samples were collected at fixed time intervals for 36 h. The concentrations of theophylline were measured with TDX (Abbott Diagnostics, Irving, Tex.), and clearance was calculated. Theophylline clearance was used to individualize subsequent doses to achieve average steady-state theophylline concentrations in plasma of 10 mg/liter. Individualized theophylline doses were administered every 8 h until steady-state conditions were reached. Theophylline clearance was determined again at steady state and on days 7 and 8. On day 8, ofloxacin (400 mg every 12 h) was given concomitantly with theophylline. Theophylline clearance was measured again on day 12, after the last theophylline dose. Administration of ofloxacin for 1 day did not change theophylline clearance, but coadministration for 4 days significantly decreased theophylline clearance by 12.1% (P less than 0.05). The area under the concentration-time curve for theophylline increased 9.9% (P less than 0.05), and average steady-state concentrations in plasma increased 10.3% (P less than 0.05). Despite changes in clearance, adverse effects of theophylline did not increase during coadministration of ofloxacin. Although statistically significant, the interaction between ofloxacin and theophylline is unlikely to be of major clinical importance.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
March 1977, The Journal of allergy and clinical immunology,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
September 1984, Pharmaceutical research,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
May 1982, Israel journal of medical sciences,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
March 1984, Archives of internal medicine,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
November 1981, Annals of internal medicine,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
April 1989, The American journal of medicine,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
October 1988, The American journal of medicine,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
October 1989, Clinical pharmacology and therapeutics,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
January 1988, European journal of clinical pharmacology,
S L Gregoire, and T H Grasela, and J P Freer, and K J Tack, and J J Schentag
November 1979, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!